# Mosaic Window

MOSAIC Window is a curated subset of the groundbreaking MOSAIC dataset, available through K Pro. It includes spatial omics and multimodal data from **60 patients** across five cancer types:

* **BLCA (Bladder Cancer):** 15 patients
* **OV (Ovarian Cancer):** 15 patients
* **GBM (Glioblastoma):** 10 patients
* **DLBCL (Diffuse Large B-cell Lymphoma):** 10 patients
* **MESO (Mesothelioma):** 10 patients

This unique resource enables researchers to explore tumor biology at near single-cell resolution, providing detailed insight into tumor and immune cell interactions.

<figure><img src="https://1034377358-files.gitbook.io/~/files/v0/b/gitbook-x-prod.appspot.com/o/spaces%2FTmCjUj6W0sltjW7q2vBp%2Fuploads%2FwJRKqDfBfCniUyTJ5PYk%2Fimage.png?alt=media&#x26;token=0bb5f795-dd66-4eb1-9b89-ee486c08fcaf" alt=""><figcaption></figcaption></figure>

#### **MOSAIC Window Patient Details**

**BLCA (15 patients):**

* Stage II and III urothelial carcinoma (one squamous cell carcinoma)
* Derived from upfront cystectomies
* Most patients receiving complete lymph node dissection
* Some treated with adjuvant chemotherapy, chemotherapy, or immune checkpoint inhibitors (ICI) at relapse, with or without radiotherapy

**OV (15 patients):**

* FIGO stage II to IV high grade serous carcinoma
* 7 baseline, 2 post-NACT, 6 relapse lesions
* Treated by upfront or post-NACT interval debulking surgeries and chemotherapy
* Additional treatments: Bevacizumab, PARP inhibitors, and ICI in first or later lines

**GBM (10 patients):**

* Glioblastoma as per WHO 2021 definition, all IDH wildtype
* 6 unmethylated and 4 methylated MGMT promoter samples
* Obtained from baseline surgery before standard adjuvant therapy
* 1 to 3 brain tumor sites, tumor sizes 27 to 80mm diameter
* 5 patients received Bevacizumab at relapse

**DLBCL (10 patients):**

* Ann Arbor stage III or IV
* 3 Activated B-cell-like type (ABC), 6 Germinal center B-cell group (GCB), 1 unknown subtype
* Obtained at baseline before R-CHOP therapy
* Targeted interventions at relapse

**MESO (10 patients):**

* Stage I to III pleural mesotheliomas
* 5 epithelioid, 5 biphasic
* 9 baseline biopsies/surgeries, 1 post-NACT sample
* 4 patients treated by NACT (1 partial response, 3 progressive diseases)
* 4 patients received anti-PD-1 ICI at relapse (monotherapy or combination with anti-CTLA4)